A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Study Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of SNDX-5613 in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations in KMT2A, NPM1, or NUP98 genes.

Conditions

Acute Myeloid Leukemias

Interventions / Drugs

SNDX-5613 Chemotherapy Regimen HiDAC

View on ClinicalTrials.gov ↗

Sponsor

SNDX

Syndax Pharmaceuticals

Oncology

C63/100

Study Details

Enrollment76 participants

Primary Completion—

Lead SponsorSyndax Pharmaceuticals

Data Retrieved2026-04-11 04:27:50.896954+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.